OR WAIT 15 SECS
Agilent Technologies has announced that it has entered into a definitive agreement to acquire the privately held ProZyme, Inc., a provider of glycan analysis reagents, kits, and standards.
Agilent Technologies (Santa Clara, California, USA) has announced that it has entered into a definitive agreement to acquire the privately held ProZyme, Inc. (Hayward, California, USA), a provider of glycan analysis reagents, kits, and standards. The acquisition will expand Agilent’s portfolio of biopharmaceutical consumables in the growing glycan market.
Founded in 1990, ProZyme is a developer and manufacturer of glycan reagents, kits, and standards, which are required for efficient sample preparation in the analysis of free glycans. Glycobiology, which is the study of the structure, function, and biology of carbohydrates, also called glycans, is a fastâgrowing and important field of study in life sciences. Glycans play diverse roles in biotherapeutics, novel drug development, the study of bacterial physiology, and proteomics research.
“Glycan analysis is essential to the discovery, development, and quality control testing of the ever-growing pipeline of biotherapeutic drug products,” said Padraig McDonnell, Vice President and General Manager of Agilent’s Chemistries and Supplies Division. “This acquisition provides greater scale to our biopharma consumables business and enhances our value proposition by enabling complete glycan liquid chromatography and mass spectrometry workflow solutions.”